Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice

Int J Obes (Lond). 2017 Jun;41(6):935-944. doi: 10.1038/ijo.2017.52. Epub 2017 Feb 21.

Abstract

Objective: Midlife obesity affects cognition and increases risk of developing dementia. Recent data suggest that intake of the short chain fatty acid butyrate could improve memory function, and may protect against diet-induced obesity by reducing body weight and adiposity.

Subjects: We examined the impact of a high-fat diet (HFD) followed by intervention with 5% (w/w) dietary butyrate, on metabolism, microbiota, brain function and structure in the low-density-lipoprotein receptor knockout (LDLr-/-) mouse model in mid and late life.

Results: In mid-adult mice, 15 weeks of HFD-induced adiposity, liver fibrosis and neuroinflammation, increased systolic blood pressure and decreased cerebral blood flow, functional connectivity assessed with neuroimaging. The subsequent 2 months butyrate intervention restored these detrimental effects to chow-fed control levels. Both HFD and butyrate intervention decreased variance in fecal microbiota composition. In late-adult mice, HFD showed similar detrimental effects and decreased cerebral white and gray matter integrity, whereas butyrate intervention attenuated only metabolic parameters.

Conclusion: HFD induces detrimental effects in mid- and late-adult mice, which can be attenuated by butyrate intervention. These findings are consistent with reported associations between midlife obesity and cognitive impairment and dementia in humans. We suggest that butyrate may have potential in prevention and treatment of midlife obesity.

MeSH terms

  • Adiposity / drug effects*
  • Animals
  • Butyrates / pharmacology*
  • Cerebrovascular Circulation / drug effects*
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / physiopathology
  • Diet, High-Fat / adverse effects*
  • Disease Models, Animal
  • Hypertension / drug therapy
  • Hypertension / physiopathology
  • Inflammation / drug therapy*
  • Inflammation / physiopathology
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / physiopathology
  • Male
  • Mice
  • Mice, Obese
  • Neuroprotective Agents / pharmacology*

Substances

  • Butyrates
  • Neuroprotective Agents